Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | SERPINA3 | P01011 | 1/20 | 0.38 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.37 |
| ▸ | POLA1 | P09884 | 2/20 | 0.36 |
| ▸ | POLG | P54098 | 2/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HPRT1 | P00492 | 3/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2606977 | 0.89 | POLB (0.44) | POLBFGFR1HDAC1SERPINA3SLC22A6 | |
| SCHEMBL2606981 | 0.88 | POLB (0.43) | POLBFGFR1HDAC1SERPINA3SLC22A6 | |
| SCHEMBL2606976 | 0.88 | POLB (0.43) | POLBFGFR1HDAC1SERPINA3SLC22A6 | |
| SCHEMBL2606919 | 0.88 | POLB (0.43) | POLBFGFR1HDAC1SERPINA3SLC22A6 | |
| SCHEMBL2606852 | 0.87 | POLB (0.42) | POLBFGFR1HDAC1SERPINA3SLC22A6 | |
| SCHEMBL2734840 | 0.87 | POLB (0.43) | POLBFGFR1HDAC1SERPINA3 | |
| SCHEMBL2606930 | 0.86 | POLB (0.42) | POLBFGFR1HDAC1SERPINA3SLC22A6 | |
| SCHEMBL2606935 | 0.85 | POLB (0.44) | POLBFGFR1HDAC1SERPINA3SLC22A6 | |
| SCHEMBL2734826 | 0.85 | POLB (0.62) | POLBFGFR1HDAC1CCNE1CDK2 | |
| SCHEMBL2606978 | 0.84 | POLB (0.46) | POLBFGFR1HDAC1SERPINA3SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268802-B2 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8088754-B2 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090291922-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-7553825-B2 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-20090149400-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149400-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | CCNY, CCNO, CCNB3 | POLB 82/4885FGFR1 1503/4885HDAC1 1229/4885 |
| US-20090291922-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | CCNY, CCNO, CCNB3 | POLB 82/4885FGFR1 1503/4885HDAC1 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.